UCLA researchers have developed AlloCAR70-NKT, an off-the-shelf allogeneic CAR-engineered natural killer T cell therapy targeting CD70, demonstrating multipronged efficacy against metastatic renal cell carcinoma (RCC) in preclinical models. This approach potentially offers rapid, accessible immunotherapy without patient-specific customization delays. Separately, Lund University scientists identified transcription factors capable of reprogramming cells into dendritic immune cells, enhancing immunotherapy prospects. Additionally, novel small molecule molecular glues and protein degraders targeting cancer-associated proteins such as RBM39 and SMARCA2 show promise in oncology drug development, underscoring the growing sophistication of immunomodulatory agents.